Strata Skin Sciences, Inc.

Strata Skin Sciences, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of December 31, 2025, Strata Skin Sciences, Inc. has 5.89M shares outstanding.

As of December 31, 2025, Strata Skin Sciences, Inc. maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 559.42, indicating elevated leverage, while an interest coverage ratio of -0.81 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Strata Skin Sciences, Inc. posted a negative return on equity (ROE) of -164.59, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -19.82, reflecting losses generated across the asset base. The company generates approximately 284,222.22 in revenue per employee across its workforce of 108.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.12 indicates how many times Strata Skin Sciences, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on November 4, 2026, Strata Skin Sciences, Inc.'s stock has declined approximately 99.99% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.47.

Over the twelve months ended December 31, 2025, Strata Skin Sciences, Inc. generated 30.70M in revenue and converted that into -6.48M in net income, yielding earnings per share of -1.39. EBITDA reached -1.59M, while operating income came in at -6.06M.

As of December 31, 2025, Strata Skin Sciences, Inc. holds 7.91M in cash and equivalents against 16.27M in total debt, resulting in a net debt position of 7.44M. Total book value stands at 2.91M, with working capital of -11.14M providing operational flexibility.

Strata Skin Sciences, Inc. produced -2.79M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -1.47M in capital expenditures, free cash flow totaled -4.26M - equivalent to -0.91 per share.

Over the twelve months ended December 31, 2025, Strata Skin Sciences, Inc. posted a gross margin of 57.83, reflecting its pricing power and cost economics. The operating margin of -19.74 and net profit margin of -21.13 provide insight into operational efficiency.

Strata Skin Sciences, Inc.'s most recent stock split took place on June 7, 2024 with a 10:1 split ratio.